Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • heart failure
  • Page 2
Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis
Posted inCardiology Diabetes & Endocrinology Specialties

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

Posted by MedXY By MedXY 09/07/2025
In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF in hospitalized patients.
Read More
Fontan Circulatory Failure and Heart Transplant Survival: Insights from a Multicenter Retrospective Cohort Study
Posted inCardiology Specialties

Fontan Circulatory Failure and Heart Transplant Survival: Insights from a Multicenter Retrospective Cohort Study

Posted by MedXY By MedXY 09/06/2025
This study identifies key Fontan circulatory failure morbidities impacting survival from heart transplant waitlisting through one year post-transplant, highlighting cyanosis and frequent hospitalizations as critical risk factors.
Read More
Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial
Posted inCardiology Public Health Specialties

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial

Posted by MedXY By MedXY 09/06/2025
The DANFLU-2 trial reveals that high-dose influenza vaccine significantly reduces hospitalization for influenza and cardiovascular events in older adults, including those with heart failure, compared to the standard-dose vaccine.
Read More
PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients
Posted inCardiology Clinical Updates Public Health Specialties

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

Posted by MedXY By MedXY 09/03/2025
The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.
Read More
Myocardial T1 Mapping and Extracellular Volume: Emerging Prognostic Tools in Heart Failure and Non-Ischaemic Dilated Cardiomyopathy
Posted inCardiology Clinical Updates news Radiology Specialties

Myocardial T1 Mapping and Extracellular Volume: Emerging Prognostic Tools in Heart Failure and Non-Ischaemic Dilated Cardiomyopathy

Posted by MedXY By MedXY 09/03/2025
Cardiac MRI T1 mapping and extracellular volume fraction (ECV) provide noninvasive markers of myocardial fibrosis, showing consistent prognostic value across heart failure subtypes and non-ischaemic dilated cardiomyopathy for adverse cardiovascular outcomes.
Read More
Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial
Posted inCardiology Clinical Updates news Specialties

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

Posted by MedXY By MedXY 09/02/2025
The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer adverse events.
Read More
Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights
Posted inCardiology news Specialties

Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights

Posted by MedXY By MedXY 09/02/2025
Bayesian modelling of combined systolic and diastolic function trajectories in older adults reveals distinct patterns predicting heart failure subtypes and identifies potential proteomic targets for therapy.
Read More
Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics
Posted inCardiology news Specialties

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

Posted by MedXY By MedXY 09/02/2025
This study integrates longitudinal systolic and diastolic cardiac function measures using Bayesian modeling to identify trajectories associated with distinct heart failure subtypes and proteomic signatures, enhancing risk prediction and therapeutic target discovery.
Read More
Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care
Posted inAI Cardiology news Specialties

Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care

Posted by MedXY By MedXY 09/02/2025
Mobile app-assisted screening in primary care settings identified new heart failure cases in one-third of at-risk patients, especially those with preserved ejection fraction, highlighting a promising route for early diagnosis.
Read More
Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension
Posted inCardiology Clinical Updates news Specialties

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

Posted by MedXY By MedXY 08/31/2025
Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.
Read More
Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management
Posted inCardiology Clinical Updates news Specialties

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

Posted by MedXY By MedXY 08/30/2025
The DIGIT-HF trial sheds new light on digitoxin's role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.
Read More
Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients
Posted inCardiology news Specialties

Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients

Posted by MedXY By MedXY 08/30/2025
The DIGIT-HF trial reveals that adding low-dose digitoxin to standard heart failure treatment reduces hospitalization and all-cause mortality in symptomatic HFrEF patients, highlighting a potential resurgence for this historic cardiac glycoside under strict dosing protocols.
Read More
Heart Failure Isn’t Scary — Ignoring Early Signs Is: Prevention for 6 High-Risk Groups
Posted inCardiology news Specialties

Heart Failure Isn’t Scary — Ignoring Early Signs Is: Prevention for 6 High-Risk Groups

Posted by MedXY By MedXY 08/27/2025
Heart failure is a serious but manageable condition. Recognizing early symptoms and understanding risk factors can save lives. Here’s a comprehensive guide on prevention, diagnosis, and management for both the public and health professionals.
Read More
Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF
Posted inCardiology news Specialties

Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF

Posted by MedXY By MedXY 08/19/2025
Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.
Read More
Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome
Posted inCardiology Clinical Updates Nephrology news Specialties

Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome

Posted by MedXY By MedXY 08/17/2025
A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.
Read More
Left Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction
Posted inCardiology Clinical Updates news Specialties

Left Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction

Posted by MedXY By MedXY 08/17/2025
This study explores the Left Atrial Coupling Index as a key predictor in heart failure patients with preserved ejection fraction.
Read More
Risks and Realities of Withdrawing Heart Failure Medications After Ejection Fraction Improvement
Posted inCardiology news Specialties

Risks and Realities of Withdrawing Heart Failure Medications After Ejection Fraction Improvement

Posted by MedXY By MedXY 08/17/2025
Withdrawal of renin-angiotensin inhibitors and mineralocorticoid receptor antagonists in patients with heart failure and improved ejection fraction significantly increases 1-year cardiovascular mortality and hospitalization risks; beta-blocker withdrawal shows varied effects based on EF.
Read More
Optimizing Blood Transfusion Strategies in Acute Myocardial Infarction with Anemia and Heart Failure: Insights from the MINT Trial
Posted inAnesthesiology Cardiology Specialties

Optimizing Blood Transfusion Strategies in Acute Myocardial Infarction with Anemia and Heart Failure: Insights from the MINT Trial

Posted by MedXY By MedXY 08/17/2025
The MINT trial reveals that liberal transfusion strategies in MI patients with anemia, including those with heart failure, reduce adverse outcomes compared to restrictive transfusion, supporting a tailored approach to transfusion management.
Read More
Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings
Posted inCardiology Specialties

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

Posted by MedXY By MedXY 08/17/2025
The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.
Read More
Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial
Posted inCardiology Specialties

Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial

Posted by MedXY By MedXY 08/17/2025
Transcatheter edge-to-edge repair (TEER) offers a safe, effective option to reduce tricuspid regurgitation severity, improve quality of life, and lower heart failure hospitalizations up to two years, including in patients with cardiac implantable electronic device leads.
Read More

Posts pagination

Previous page 1 2 3 Next page
  • Nirsevimab Outperforms Maternal Vaccination in Reducing Severe RSV Outcomes: Insights from Comparative Real-World Evidence
  • Cyst Fluid Genomics Redefine Risk: Mixed-Type IPMNs Harbor Greater Malignant Potential Than Branch-Duct Variants
  • PROMIS Measures Proven Valid and Responsive for Assessing the Multidimensional Impact of Chronic Skin Diseases
  • First-Trimester Z-Drug Exposure Does Not Increase Overall Risk of Congenital Malformations
  • FDA Modernization Act 3.0: A Legislative Catalyst for the Post-Animal Testing Era in Clinical Pharmacology
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in